Gulf healthcare systems shift from importing excellence to building it locally

For decades, patients with serious health conditions across the Gulf had little choice: seek treatment abroad. London drew those needing cardiac surgery. Houston attracted oncology patients. Munich hosted those requiring complex neurology. The region assumed that world-class medicine existed only elsewhere.

That assumption no longer holds.

The Gulf Cooperation Council’s real healthcare story extends far beyond the construction of modern hospitals. Instead, it centers on whether the region will simply host international medicine or genuinely own it which is a distinction that carries profound implications. Hosting means importing foreign brands and importing technology. Owning demands actively building medical expertise, conducting research, and shaping the evolution of medicine.

Governments and private institutions across the GCC are investing unprecedented sums into healthcare infrastructure, recruiting top talent, and acquiring cutting-edge technology. The visible results impress observers worldwide, yet one fundamental question remains: are these systems merely delivering care, or are they creating lasting medical capacity?

From international brands to local expertise

Cleveland Clinic Abu Dhabi exemplifies the first phase of the GCC’s healthcare evolution—the legitimacy phase. By establishing partnerships with globally recognized institutions like Johns Hopkins, King’s College Hospital, and Cleveland Clinic itself, the region demonstrated that patients no longer needed to travel abroad for sophisticated treatments.

Now in its tenth year, Cleveland Clinic Abu Dhabi has served over 6.8 million patients and completed more than 175,000 surgical procedures. International patient numbers climbed 35 percent between 2023 and 2024 alone. The hospital earned Centre of Excellence status across multiple disciplines, including multi-organ transplantation. In 2024, it performed the UAE’s first combined heart and lung transplant. By 2025, it had conducted the region’s first robotic lung transplant.

This represents hosting medicine at its finest—credible, high-quality, and capable of drawing international patients. Yet hosting differs fundamentally from owning.

Ownership begins where new buildings end. It emerges through clinical culture, research contributions, and the capacity to generate medical knowledge rather than simply applying existing knowledge. King Faisal Specialist Hospital and Research Centre in Riyadh clearly demonstrates this distinction.

Ranked first in the Middle East and Africa and twelfth globally among the world’s top 250 academic medical centers in 2026, King Faisal has moved beyond merely showcasing capability. Within two years, the hospital performed the world’s first fully robotic heart transplant, the world’s first fully robotic liver transplant, and the world’s first robotic-assisted artificial heart pump implantation. Its robotic surgery program alone completed 1,370 procedures in 2024, marking a 28 percent year-over-year increase.

The distinction becomes obvious: equipment arrives quickly, but clinical culture takes years to develop. A surgical robot can be installed in a matter of months. The systems supporting it, such as training protocols, peer review processes, research infrastructure, and outcomes tracking, require years to mature. That timeline difference defines whether an institution hosts capability or owns it.

Clemenceau Medical Centre Dubai, King’s College Hospital locations in Dubai and Saudi Arabia, Johns Hopkins Aramco Healthcare, and Sidra Medicine in Doha increasingly demonstrate this ownership mentality. These institutions no longer measure success by importing global brands but by building permanent medical excellence from within.

The Genomics opportunity

Clinical culture currently defines ownership, but genomics may define it tomorrow.

The Arab genome remains strikingly absent from global medical research databases. Modern medicine, from treatment guidelines to pharmaceutical development, rests predominantly on Western population data. This absence creates both a disadvantage and an unprecedented opportunity.

Whichever institution first builds population-specific genomic insights achieves more than local improvement. That institution contributes to, and potentially reshapes, global medicine itself.

Sidra Medicine in Doha, working alongside King’s College London, has created one of the most comprehensive genomic maps of the Qatari population. The research connects specific genetic variants to diseases and serves as a global resource for studying Arab ancestries in medicine.

Sidra launched clinical trials targeting Arab populations specifically and implemented whole genome sequencing for critically ill children, dramatically shortening diagnostic timelines. In Saudi Arabia, King Faisal participates centrally in the Saudi Human Genome Programme, connecting genetic research directly to national healthcare strategy and disease patterns specific to the region.

The UAE builds parallel capacity through the UAE Genomics Council, which has developed national infrastructure since 2021 under data protection legislation. M42, which owns Cleveland Clinic Abu Dhabi, combines genetic data, biomarkers, and artificial intelligence, in partnership with GE HealthCare and AstraZeneca, to advance diagnostics and liquid biopsy testing.

This represents the GCC’s most overlooked advantage. Unlike established health systems burdened by fragmented historical data, the region is building genomic and clinical infrastructure from the ground up, with population-specific data embedded from the outset. Executed successfully, this positions the region for leadership in precision medicine, particularly in hereditary disease, pharmacogenomics, and metabolic conditions.

Building trust rather than chasing patients

Much international coverage frames this as a competition for medical tourism. The GCC healthcare market reached approximately USD 9.6 billion in 2025 and is projected to exceed double that within ten years.

Patient travel numbers, however, reflect outcomes, not objectives. Patients do not select destinations based on new buildings alone. They choose based on trust—confidence in outcomes, confidence in expertise, and confidence that the system prioritizes their needs.

Joint Commission International accreditation has become standard among leading hospitals. The next competitive shift will emerge from transparent clinical outcomes reporting, which presents far greater challenges than securing external accreditation. Institutions that first publish and compete openly on outcomes data will fundamentally reshape regional markets. Few hospitals currently do so with meaningful transparency.

When they do, the gap between hosting medicine and owning it will become visible and measurable to patients, physicians, and global competitors alike.

The path forward

The race to bring world-class medicine to the Gulf has largely concluded. The next competition proves harder and more valuable.

Medical institutions that will shape this region’s future are those constructing what money cannot buy: clinical cultures earned through years of commitment, research programs generating new knowledge rather than reproducing existing protocols, and control of population-specific data that makes medicine here more precise, more relevant, and ultimately more valuable than anything brought from abroad.

The genomic investments being made today by institutions across Doha, Riyadh, and Abu Dhabi signal which direction the region is moving. So too does the consistent accumulation of surgical achievements at institutions that invested seriously long before the current investment boom attracted media attention.

The details separating genuine leaders will not appear at hospital opening ceremonies. They will emerge in outcomes data, in published research, and in the patients who travel here not because other options have disappeared, but because this is where the finest care exists.